|Over a week ago|
Optinose transferred with an Outperform at RBC Capital » 16:5604/0604/06/21
RBC Capital transferred…
RBC Capital transferred coverage of Optinose to analyst Daniel Busby, also keeping an Outperform rating and $17 price target on the stock.
|Over a month ago|
Two new option listings and two option delistings on March 18th » 08:3003/1803/18/21
OPTN, SRTS, QEP, RLH
New option listings for…
New option listings for March 18th include OptiNose Inc (OPTN) and Sensus Healthcare (SRTS). Option delistings effective March 18th include Qep Resources Inc (QEP) and Red Lion Hotels (RLH).
Optinose expects topline results from OPN-019 study in 2Q21 » 07:0603/0303/03/21
In June 2020, the Company…
In June 2020, the Company announced the initiation of development of a new product candidate, OPN-019, which combines its proprietary intranasal Exhalation Delivery System with an antiseptic. Because components of the drug-device combination product candidate, including both the active drug and delivery device, are currently commercially available in the U.S., the Company anticipates a potential streamlined and accelerated development. Subsequent to a pre-Investigational New Drug submission the Company is engaged with FDA regarding an IND and clinical development pathway. The Company has performed in vitro testing against SARS-CoV-2 with a candidate formulation in which a 4-log reduction in virus count was produced. In addition, the Company performed tests against other pathogens. For most pathogens tested, 3-log to 6-log reductions in virus count were observed. In April 2021, the Company expects to initiate a randomized, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no symptoms. This pilot study being conducted in Mexico will evaluate both the magnitude and duration of viral load reduction after a single dose of OPN-019. The Company expects top-line results from this study in second quarter 2021. The Company is focused on supporting the initial stages of development within our current operating expense guidance and intend to seek grants, partnerships, and/or other sources of capital to fund future development.
Optinose expects topline results from one XHANCE trial by end of 2021 » 07:0503/0303/03/21
The Company expects…
The Company expects top-line results from one of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis by the end of 2021 and the other in the first half of 2022. Pauses in patient enrollment, due to the COVID-19 pandemic, at some clinical trial sites changed the Company's prior expectation of top-line results from both trials in the second half of 2021.
Optinose expects Q1 XHANCE revenues to decrease vs. Q4 » 07:0503/0303/03/21
Revenue consensus $18.65M.
Optinose sees FY21 XHANCE revenues at least $80M » 07:0403/0303/03/21
Revenue consensus $103.19M. The Company expects XHANCE net revenues for the full year of 2021 to be at least $80 million. This includes the Company's expectation that first quarter 2021 XHANCE net revenue will decrease compared to fourth quarter 2020. The primary driver of the sequential decrease to revenue is the Company's expectation that XHANCE average net revenue per prescription for the first quarter of 2021 will be between $120 and $140, due to typical early-year effects on price and volume related to patient insurance that the Company believes are common for chronic treatments that derive a significant proportion of total prescriptions from refills. The Company expects XHANCE average net revenue per prescription to improve substantially for the remainder of 2021. In addition, the Company expects full year 2021 XHANCE net revenue per prescription to increase compared to full year 2020 XHANCE net revenue per prescription of $185. The Company expects total GAAP operating expenses for 2021 to be in the range of $137 - $142 million, of which the Company expects stock-based compensation to be approximately $11 million.
Optinose reports Q4 EPS (46c), consensus (46c) » 07:0203/0303/03/21
Reports Q4 revenue…
Reports Q4 revenue $16.3M, consensus $17.93M. "I am proud of how the team at Optinose responded to the market disruptions created by the global pandemic, enabling us to deliver 70% year-over-year growth of prescriptions for XHANCE," stated CEO Peter Miller. "As a launch-stage product, new patient starts are a critical driver of future success. Following pandemic-related disruption in second quarter, we achieved consecutive all-time highs for new prescriptions of XHANCE in third and fourth quarter 2020. Looking ahead, we believe we expect sustained or increased XHANCE growth in 2021. Our expectations for first quarter 2021 include typical early-year effects on price and volume related to patient insurance that we believe are common for chronic treatments that derive a significant proportion of total prescriptions from refills, and for full year 2021 we expect XHANCE net revenue to be at least $80 million."
|Over a quarter ago|
Optinose expects topline results from XHANCE trials in 2H21 » 07:3211/0511/05/20
The Company expects total…
The Company expects total GAAP operating expenses for 2020 to be in the range of $127 - $132 million, of which the Company expects stock-based compensation to be approximately $10 million. Previously the Company expected total GAAP operating expenses for 2020 to be in the range of $131 - $136 million, of which stock-based compensation was expected to be approximately $11 million. The Company expects top-line results from both of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis in the second half of 2021. The Company expects to draw $20 million of cash from its debt facility by early 2021, subject to continuing to meet eligibility requirements.
Optinose reports Q3 EPS (43c), consensus (52c) » 07:3111/0511/05/20
Reports Q3 revenue…
Reports Q3 revenue $15.4M, consensus $14.28M. "New and total prescriptions for XHANCE reached an all-time quarterly high in the third quarter of 2020. We are pleased with this achievement after experiencing a challenging environment in the second quarter 2020 due to significant pandemic-related declines in patient volume in ENT and Allergy offices," stated CEO Peter Miller. "As a result of increased demand and improvement in net revenue per prescription, XHANCE net revenues were $15.4 million. By exceeding the third quarter 2020 net revenue threshold specified in our debt facility, we open up the option to draw an additional $20 million to add to our cash position, which would extend our cash runway and further enable us to focus on growth. Finally, we are excited by recent events that we believe meaningfully support XHANCE growth potential as we progress into 2021. These include both our co-promotion with kaleo, which first hit the field in October and grows our sales reach and frequency, and the new publication by Brent Senior, M.D., Professor of Otolaryngology and Vice Chair of Academics and Outreach at the University of North Carolina, and others that describes the value of XHANCE in the population of patients who are still symptomatic on conventional nasal steroids."
Optinose sees Q3 XHANCE net product revenues $15.4M » 07:0210/2210/22/20
Revenue consensus $13.88M. Optinose announced preliminary XHANCE net product revenues of $15.4M for the three months ended September 30, 2020. XHANCE net product revenues increased 78% compared to the three months ended September 30, 2019, and 50% compared to the three months ended June 30, 2020. This financial information is preliminary and subject to change. The Company expects to report full financial results for the third quarter of 2020 and corporate updates before market open on Thursday, November 5, 2020.